Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Lilly Eli & Co (LLY) delivers innovative healthcare solutions through cutting-edge pharmaceutical research and global therapeutic development. This news hub provides investors and industry professionals with timely updates on corporate milestones, regulatory developments, and scientific advancements.
Access official press releases, earnings reports, and analysis of key initiatives across diabetes, oncology, and immunology research. Our curated collection ensures you stay informed about FDA decisions, partnership announcements, and manufacturing expansions without promotional bias.
Discover updates on clinical trial progress, sustainability efforts, and market leadership in biotechnology. Bookmark this page for streamlined access to verified information that supports informed decision-making in the evolving pharmaceutical landscape.
Rhea-AI Summary
Eli Lilly announced positive Phase 3 trial results for efsitora alfa, a novel once-weekly insulin treatment for type 2 diabetes. The QWINT-1, QWINT-3, and QWINT-4 trials demonstrated that efsitora met primary endpoints for A1C reduction compared to daily basal insulin. In QWINT-1, efsitora reduced A1C by 1.31% vs 1.27% for insulin glargine at 52 weeks. QWINT-3 showed 0.86% reduction vs 0.75% for insulin degludec, while QWINT-4 achieved 1.07% reduction matching insulin glargine. The drug's safety profile was comparable to common daily basal insulins, with QWINT-1 showing 40% fewer hypoglycemic events. Notably, efsitora's once-weekly dosing could eliminate over 300 injections annually. Lilly plans to submit efsitora for regulatory approval by year-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Eli Lilly announced positive Phase 3 ACHIEVE-1 trial results for orforglipron, their first-in-class oral GLP-1 receptor agonist for type 2 diabetes. The once-daily pill demonstrated significant A1C reductions of 1.3% to 1.6% from baseline across doses (3mg, 12mg, 36mg) at 40 weeks. The highest dose achieved notable weight loss of 16.0 lbs (7.9%). Up to 76.2% of participants reached target A1C levels <7%. The drug showed early efficacy within four weeks and maintained a safety profile consistent with injectable GLP-1s, with mainly gastrointestinal side effects. Importantly, orforglipron requires no food or water restrictions, potentially offering a convenient alternative to injectable treatments. Lilly plans regulatory submissions for weight management in 2025 and type 2 diabetes in 2026, with additional trial results expected later this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Eli Lilly (NYSE: LLY) has announced a definitive agreement to acquire Verve Therapeutics (Nasdaq: VERV), a clinical-stage biotech company specializing in genetic medicines for cardiovascular disease. The deal values Verve at $10.50 per share in cash ($1.0 billion), plus a CVR worth up to $3.00 per share, potentially reaching $13.50 per share ($1.3 billion total). Verve's lead program, VERVE-102, is a first-in-class in vivo gene editing treatment targeting PCSK9 for cardiovascular disease, designed as a one-time treatment for conditions like heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease. The FDA has granted Fast Track designation to VERVE-102, currently in Phase 1b trials. The acquisition price represents a 113% premium to Verve's 30-day volume-weighted average trading price, with the deal expected to close in Q3 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
Rhea-AI Summary
Eli Lilly (NYSE: LLY) announced that Zepbound's highest approved doses (12.5 mg and 15 mg) will be available in single-dose vials for $499/month through LillyDirect's Self Pay Pharmacy Solutions starting July 7, 2025. All Zepbound doses will now be accessible at $499/month or less ($349 for starter dose), regardless of insurance status. In clinical trials, adults taking Zepbound 15 mg achieved remarkable results, with average weight loss of 48 lbs (~21%) and approximately one-third losing over 58 lbs (25%). The complete range includes 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses, with pricing through the Self Pay Journey Program ranging from $349-$1,049, but capped at $499 with program benefits. The medication is indicated for adults with obesity or overweight with weight-related conditions and has shown significant efficacy in both diabetic and non-diabetic populations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
-
Rhea-AI Summary
Eli Lilly (NYSE:LLY) announced its participation in the Goldman Sachs 46th Annual Global Health Care Conference scheduled for June 10, 2025. The company's executive vice president and CFO, Lucas Montarce, will participate in a fireside chat at 8 a.m. Eastern time. Investors can access a live audio webcast of the presentation through Lilly's investor website, with a replay available for approximately 90 days following the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
-
Rhea-AI Summary
Eli Lilly (LLY) presented promising Phase 1 data for its folate receptor alpha (FRα) antibody-drug conjugate (LY4170156) in treating platinum-resistant ovarian cancer. The drug showed a 55% overall objective response rate (ORR) at the recommended Phase 2 dose of 4 mg/kg. The study included 95 patients with high-grade serous ovarian cancer, with efficacy demonstrated across all FRα expression levels, including patients previously treated with mirvetuximab soravtansine. The drug showed a favorable safety profile with common side effects including nausea (64%), anemia (40%), and fatigue (32%). Notably, no treatment-emergent neuropathy or ocular toxicity was observed. The overall disease control rate was 74% among the 58 efficacy-evaluable patients, suggesting potential significant expansion of treatment options for ovarian cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
Rhea-AI Summary
Eli Lilly (NYSE: LLY) will present data from multiple studies at the American Diabetes Association's 85th Scientific Sessions (June 20-23, 2025) in Chicago. Key presentations will feature results from several investigational drugs:
• Orforglipron: ACHIEVE-1 Phase 3 trial results for this small molecule GLP-1 receptor agonist
• Insulin efsitora alfa: QWINT-1, QWINT-3, and QWINT-4 Phase 3 trial results for this once-weekly basal insulin
• Bimagrumab: BELIEVE Phase 2b trial results evaluating this activin pathway inhibitor alone and with semaglutide
• Tirzepatide (Zepbound/Mounjaro): Multiple presentations including SURMOUNT-1 176-week data and SURMOUNT-5 comparison vs semaglutide
• Retatrutide and Eloralintide: Preclinical and early clinical data
Lilly will host an investor event on June 22 to discuss key presentations and their cardiometabolic health portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
-
Rhea-AI Summary
Eli Lilly (NYSE: LLY) has announced a definitive agreement to acquire SiteOne Therapeutics, a private biotech company specializing in sodium channel inhibitors for pain treatment. The deal, valued at up to $1.0 billion in cash, includes upfront payment and milestone-based payments. The key asset is STC-004, a Phase 2-ready Nav1.8 inhibitor being developed as a potential next-generation, non-opioid treatment for chronic pain. This acquisition aligns with Lilly's strategy to advance addiction-free pain therapies and address the growing global burden of chronic pain. The transaction is subject to customary closing conditions and will be reflected in Lilly's financial guidance upon completion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
-
Rhea-AI Summary
Eli Lilly (NYSE: LLY) will present data from multiple oncology studies at the 2025 ASCO Annual Meeting (May 30-June 3, Chicago). Key presentations include:
1. Imlunestrant: Patient-reported outcomes and safety analyses from Phase 3 EMBER-3 trial in ER+/HER2- advanced breast cancer
2. Olomorasib: Updated results from Phase 1/2 studies combining this KRAS G12C inhibitor with:
- Pembrolizumab in NSCLC
- Cetuximab in colorectal cancer
3. LY4170156: Initial results from Phase 1a/1b study of this FRα-targeting antibody-drug conjugate in platinum-resistant ovarian cancer
4. Verzenio: Analysis of BMI impact on efficacy and safety in breast cancer patients from the monarchE trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
Rhea-AI Summary
Eli Lilly's Kisunla (donanemab) has received marketing authorization in Australia for treating early symptomatic Alzheimer's disease in adults who are ApoE ε4 heterozygotes or non-carriers. This marks the 13th regulatory authorization globally for the drug.
Key clinical results from the TRAILBLAZER-ALZ 2 Phase 3 study showed that Kisunla:
- Slowed cognitive and functional decline by up to 35% compared to placebo at 18 months
- Reduced disease progression risk by 39% over the same period
The drug targets amyloid plaques and is notable as the only amyloid-targeting therapy with evidence supporting treatment discontinuation once plaques are removed. Of the estimated 600,000 Australians living with Alzheimer's, approximately 450,000 in early stages could be assessed for Kisunla treatment eligibility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
FAQ
What is the current stock price of Lilly Eli & Co (LLY)?
The current stock price of Lilly Eli & Co (LLY) is $762.73 as of June 20, 2025.
What is the market cap of Lilly Eli & Co (LLY)?
The market cap of Lilly Eli & Co (LLY) is approximately 729.0B.
Lilly Eli & Co
NYSE:LLY
LLY Rankings
LLY Stock Data
728.99B
945.64M
0.17%
83.56%
0.81%
Drug Manufacturers - General
Pharmaceutical Preparations
United States
INDIANAPOLIS